01
GLP-1 agonist
Compounded Semaglutide
From $353 / month
A weekly subcutaneous protocol. Titration set by fasting metabolic panel and tolerance, not a marketing calendar.
01
Metabolic Output
A GLP-1 practice titrated to biomarkers, not marketing.
Tirzepatide, semaglutide, and retatrutide prescribed under physician oversight. The protocol is paced against fasting insulin, HOMA-IR, lipid panel, and lean-mass preservation. Titration is the intervention.
Plate 01 · Metabolic output
Endpoint
Lean mass preserved. Visceral fat reduced.
02 · The Protocols
Titrated to the biomarker. Paced to the chart.
Therapeutic cost and cadence are reviewed together. Paneling is required before every titration.
02
GLP-1 / GIP co-agonist
Compounded Tirzepatide
From $453 / month
Dual incretin agonism for members whose metabolic complexity calls for a broader signal. Paneling is required.
03
Emerging protocol
Retatrutide Review
By consultation
Triple agonist under early clinical review. Eligibility determined by prior response, risk profile, and current evidence.
03 — What is included
- A founding physician consultation to set the metabolic endpoint.
- 503A compounded therapeutics dispatched privately to your address.
- Titration support, refill coordination, and anticipated follow-up.
- Metabolic paneling (HOMA-IR, lipid, hepatic) on cadence when indicated.
04 — Clinical posture
- Therapies are prescribed only when medically appropriate after physician review.
- Compounded formulations are patient-specific and differ from FDA-approved brand products.
- Protocol cadence is driven by paneling, tolerance, and symptom response.
- Discontinuation is a clinical option when biomarkers warrant it.
